Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A.

Eur Urol Oncol. 2018 Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. Epub 2018 Jun 6.

PMID:
31058267
2.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Feb 13. doi: 10.1007/s00345-019-02678-x. [Epub ahead of print]

PMID:
30759271
3.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
4.

Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.

Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Apr;36(4):159.e7-159.e17. doi: 10.1016/j.urolonc.2017.12.001. Epub 2017 Dec 26.

PMID:
29288008
5.

Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States.

Singla N, Fang D, Su X, Bao Z, Cao Z, Robyak H, Xiong G, Zhang L, Woldu S, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman JD, Margulis V.

Urol Oncol. 2018 Mar;36(3):88.e11-88.e18. doi: 10.1016/j.urolonc.2017.10.029. Epub 2017 Nov 23.

PMID:
29174945
6.

Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses.

Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A.

Urology. 2018 Feb;112:103-111. doi: 10.1016/j.urology.2017.08.059. Epub 2017 Dec 6.

PMID:
29079210
7.

Impact of hospital case volume on testicular cancer outcomes and practice patterns.

Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Jan;36(1):14.e7-14.e15. doi: 10.1016/j.urolonc.2017.08.024. Epub 2017 Sep 19.

PMID:
28935185
8.

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V.

J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.

PMID:
28668287
9.

Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.

Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, Laine A, Xie XJ, Choy H, Brugarolas J, Timmerman R, Hannan R.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):91-100. doi: 10.1016/j.ijrobp.2017.01.032.

10.

Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance.

Sorokin I, Canvasser NE, Margulis V, Lotan Y, Raj G, Sagalowsky A, Gahan JC, Cadeddu JA.

J Urol. 2017 Nov;198(5):1021-1026. doi: 10.1016/j.juro.2017.04.080. Epub 2017 Apr 23. Review.

PMID:
28442383
11.

Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.

Haddad AQ, Luo JH, Krabbe LM, Darwish O, Gayed B, Youssef R, Kapur P, Rakheja D, Lotan Y, Sagalowsky A, Margulis V.

BJU Int. 2017 May;119(5):741-747. doi: 10.1111/bju.13776. Epub 2017 Feb 9.

12.

A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States.

Singla N, Fang D, Su X, Bao Z, Cao Z, Jafri SM, Xiong G, Zhang L, Hutchinson R, Sagalowsky A, Lotan Y, Li X, Zhou L, Raman JD, Margulis V.

J Urol. 2017 May;197(5):1208-1213. doi: 10.1016/j.juro.2016.11.094. Epub 2016 Nov 22.

PMID:
27887951
13.

Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V.

J Urol. 2017 Mar;197(3 Pt 1):580-589. doi: 10.1016/j.juro.2016.09.078. Epub 2016 Sep 23.

PMID:
27670916
14.

Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.

Passoni N, Gayed B, Kapur P, Sagalowsky AI, Shariat SF, Lotan Y.

Urol Oncol. 2016 Nov;34(11):485.e7-485.e14. doi: 10.1016/j.urolonc.2016.05.014. Epub 2016 Sep 13.

PMID:
27637323
15.

Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma.

Singla N, Hutchinson R, Haddad A, Sagalowsky A, Lotan Y, Margulis V.

Can J Urol. 2016 Aug;23(4):8334-41.

PMID:
27544555
16.

Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues.

Chen W, Zhou J, Wu K, Huang J, Ding Y, Yun EJ, Wang B, Ding C, Hernandez E, Santoyo J, Chen H, Lin H, Sagalowsky A, He D, Zhou J, Hsieh JT.

Oncotarget. 2016 Aug 30;7(35):56842-56854. doi: 10.18632/oncotarget.10863.

17.

Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma.

Singla N, Hutchinson R, Menegaz C, Haddad AQ, Jiang L, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V.

Urology. 2016 Oct;96:44-53. doi: 10.1016/j.urology.2016.07.015. Epub 2016 Jul 18.

PMID:
27443467
18.

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned.

Gayed BA, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J, Raj G, DiMaio JM, Sagalowsky A, Margulis V.

BMC Urol. 2016 Jul 19;16(1):43. doi: 10.1186/s12894-016-0157-3.

19.

Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study.

Passoni NM, Shariat SF, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, Lotan Y.

Bladder Cancer. 2016 Jan 7;2(1):91-99.

20.

Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma.

Sheth KR, Haddad AQ, Ashorobi OS, Meissner MA, Sagalowsky AI, Lotan Y, Margulis V.

Urol Oncol. 2016 Sep;34(9):418.e9-418.e16. doi: 10.1016/j.urolonc.2016.04.009. Epub 2016 May 24.

PMID:
27234379
21.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

22.

Upper tract urothelial carcinoma: special considerations.

Hutchinson R, Haddad A, Sagalowsky A, Margulis V.

Clin Adv Hematol Oncol. 2016 Feb;14(2):101-9. Review.

PMID:
27057809
23.

The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance.

Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, Raj GV, Sagalowsky AI, Cadeddu JA.

J Urol. 2016 Aug;196(2):321-6. doi: 10.1016/j.juro.2016.02.068. Epub 2016 Feb 13.

PMID:
26880407
24.

Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?

Cost NG, Caldwell BT, Adibi M, Raj GV, Sagalowsky AI, Margulis V.

J Adolesc Young Adult Oncol. 2016 Sep;5(3):248-53. doi: 10.1089/jayao.2015.0057. Epub 2016 Feb 12.

PMID:
26871870
25.

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B.

Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461579
26.

Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma.

Haddad AQ, Jiang L, Cadeddu JA, Lotan Y, Gahan JC, Hynan LS, Gupta N, Raj GV, Sagalowsky AI, Margulis V.

Urology. 2015 Dec;86(6):1146-52. doi: 10.1016/j.urology.2015.09.015. Epub 2015 Sep 28.

PMID:
26416007
27.

Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.

Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, Arriaga Y, Lotan Y.

Can J Urol. 2015 Aug;22(4):7865-75.

PMID:
26267024
28.

Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9].

Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF.

Eur Urol. 2015 Jul;68(1):171. doi: 10.1016/j.eururo.2015.02.007. Epub 2015 Feb 18. No abstract available.

PMID:
26088736
29.

Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus.

Haddad AQ, Leibovich BC, Abel EJ, Luo JH, Krabbe LM, Thompson RH, Heckman JE, Merrill MM, Gayed BA, Sagalowsky AI, Boorjian SA, Wood CG, Margulis V.

Urol Oncol. 2015 Sep;33(9):388.e1-9. doi: 10.1016/j.urolonc.2015.04.010. Epub 2015 May 23.

PMID:
26004163
30.

Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?

Krabbe LM, Bagrodia A, Westerman ME, Gayed BA, Haddad AQ, Sagalowsky AI, Shariat SF, Kapur P, Lotan Y, Margulis V.

World J Urol. 2016 Jan;34(1):105-12. doi: 10.1007/s00345-015-1584-6. Epub 2015 May 20.

PMID:
25991599
31.

Editorial Comment.

Sagalowsky AI.

J Urol. 2015 Aug;194(2):329. doi: 10.1016/j.juro.2015.03.134. Epub 2015 May 16. No abstract available.

PMID:
25986987
32.

TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma.

Youssef RF, Krabbe LM, Shariat SF, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Bensalah K, Kassouf W, Margulis V.

World J Urol. 2015 Dec;33(12):1965-72. doi: 10.1007/s00345-015-1566-8. Epub 2015 May 10.

PMID:
25957592
33.

Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.

Gayed BA, Gillen J, Christie A, Peña-Llopis S, Xie XJ, Yan J, Karam JA, Raj G, Sagalowsky AI, Lotan Y, Margulis V, Brugarolas J.

BMC Urol. 2015 Apr 3;15:24. doi: 10.1186/s12894-015-0019-4.

34.

Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma.

Singla N, Gayed BA, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O, Sagalowsky A, Lotan Y, Derweesh I, Margulis V.

Urol Oncol. 2015 Jun;33(6):268.e1-7. doi: 10.1016/j.urolonc.2015.03.006. Epub 2015 Apr 7.

PMID:
25862284
35.

Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for bladder cancer.

Haddad AQ, Singla N, Gupta N, Raj GV, Sagalowsky AI, Margulis V, Lotan Y.

Urology. 2015 Apr;85(4):876-82. doi: 10.1016/j.urology.2014.12.024.

PMID:
25817110
36.

Editorial comment.

Sagalowsky AI.

Urology. 2015 Apr;85(4):867-8. doi: 10.1016/j.urology.2014.11.047. No abstract available.

PMID:
25817109
37.

Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus.

Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky A, Pedrosa I, Choy H, Brugarolas J, Timmerman RD.

Cancer Biol Ther. 2015;16(5):657-61. doi: 10.1080/15384047.2015.1026506.

38.

Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results.

Gayed BA, Bagrodia A, Gaitonde M, Krabbe LM, Meissner M, Kapur P, Youssef RF, Sagalowsky A, Lotan Y, Margulis V.

Urol Oncol. 2015 Jan;33(1):18.e21-18.e26. doi: 10.1016/j.urolonc.2014.09.017. Epub 2014 Nov 7.

PMID:
25454486
39.

Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract.

Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V.

J Urol. 2015 May;193(5):1486-93. doi: 10.1016/j.juro.2014.11.007. Epub 2014 Nov 11.

PMID:
25451830
40.

Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.

Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclerq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V.

Urology. 2014 Nov;84(5):1134-40. doi: 10.1016/j.urology.2014.07.050. Epub 2014 Oct 24.

PMID:
25443916
41.

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S.

Nat Genet. 2015 Jan;47(1):13-21. doi: 10.1038/ng.3146. Epub 2014 Nov 17.

42.

Editorial comment.

Sagalowsky AI.

Urology. 2014 Dec;84(6):1334. doi: 10.1016/j.urology.2014.07.052. Epub 2014 Oct 5. No abstract available.

PMID:
25288576
43.

Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.

Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V.

Cancer. 2015 Jan 1;121(1):43-50. doi: 10.1002/cncr.28976. Epub 2014 Sep 3.

44.

Editorial comment.

Sagalowsky AI.

Urology. 2014 Aug;84(2):363. doi: 10.1016/j.urology.2014.03.044. No abstract available.

PMID:
25065988
45.

Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract.

Chung PH, Krabbe LM, Darwish OM, Westerman ME, Bagrodia A, Gayed BA, Haddad AQ, Kapur P, Sagalowsky AI, Lotan Y, Margulis V.

Urol Oncol. 2014 Oct;32(7):981-8. doi: 10.1016/j.urolonc.2014.02.018. Epub 2014 Jul 9.

PMID:
25022858
46.

Twenty-year focal relapse of prostate cancer.

Baumgarten A, Sagalowsky AI.

Curr Urol Rep. 2014 Jul;15(7):418. doi: 10.1007/s11934-014-0418-1. No abstract available.

PMID:
24842680
47.

Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort.

Haddad AQ, Wood CG, Abel EJ, Krabbe LM, Darwish OM, Thompson RH, Heckman JE, Merril MM, Gayed BA, Sagalowsky AI, Boorjian SA, Margulis V, Leibovich BC.

J Urol. 2014 Oct;192(4):1050-6. doi: 10.1016/j.juro.2014.03.111. Epub 2014 Apr 2.

PMID:
24704115
48.

Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.

Cost NG, Lubahn JD, Adibi M, Romman A, Wickiser JE, Raj GV, Sagalowsky AI, Margulis V.

J Urol. 2014 May;191(5 Suppl):1485-90. doi: 10.1016/j.juro.2013.08.047. Epub 2014 Mar 26.

PMID:
24679874
49.

Is extended lymphadenectomy of beneficial therapeutic value for T2 urothelial cancer?

Skinner EC, Sagalowsky AI.

J Urol. 2014 May;191(5):1206-8. doi: 10.1016/j.juro.2014.02.040. Epub 2014 Feb 20. No abstract available.

PMID:
24560793
50.

Editorial comment.

Sagalowsky AI.

Urology. 2014 Feb;83(2):398-9. doi: 10.1016/j.urology.2013.10.040. No abstract available.

PMID:
24468514

Supplemental Content

Loading ...
Support Center